ObsEva SA to present at the H.C Wainwright 22nd Annual Global Investment Virtual Conference, September 14-16, 2020
ObsEva SA (NASDAQ: OBSV), a biopharmaceutical company focused on women's reproductive health, announced that CEO Ernest Loumaye will present at the H.C Wainwright 22nd Annual Global Investment Virtual Conference from September 14-16, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ObsEva SA (NASDAQ: OBSV), a biopharmaceutical company focused on women's reproductive health, announced that CEO Ernest Loumaye will present at the H.C Wainwright 22nd Annual Global Investment Virtual Conference from September 14-16, 2020. His presentation is scheduled for September 16 at 12:00 p.m. ET. Investors can access the live presentation through the Events Calendar on ObsEva's website at www.ObsEva.com. The company is developing therapies for conditions like endometriosis and uterine fibroids.
Details
News Market Reaction – OBSV
The recorded move for OBSV in the trading session of this news was -1.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Geneva, Switzerland and Boston, MA – September 8, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that CEO Ernest Loumaye will present an update on the Company and its pipeline at the H.C Wainwright 22nd Annual Global Investment Virtual Conference taking place September 14-16, 2020.
Mr. Loumaye’s presentation will take place on Wednesday September 16 at 12:00 p.m. Eastern Time (ET). A live presentation link will be available under “Events Calendar” in the investors section of ObsEva’s website at www.ObsEva.com
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
For further information, please contact:
CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact
Mario Corso
Vice President, Investor Relations
mario.corso@obseva.com
+1 857 972 9347 Office
+1 781 366 5726 Mobile
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.